| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9499bfaa0f7c82a0a4bc86f34406d477 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-688
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-688 |
| filingDate |
2017-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46492f4aa991012de1545e38a5701431
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_280f36fd5fb2d68b997f0b17a8616e4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94a1fbd9bca58d822f565b57cceb100b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7247ef97c68ccd1eeb37504f8e9d1b8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f928083d36910398fb0027ef4519663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c71d7b28a6eceb1623518b14b65d134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e781102dfde19a6d1a9d2a0e7f93d527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09e87ab43f27fa4d7d915ec491f00a36 |
| publicationDate |
2021-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11166967-B2 |
| titleOfInvention |
Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of PAR-related diseases |
| abstract |
The present invention relates to compounds for use in the prevention and/or treatment of PAR-related diseases, such as for example: pain and ocular disorders. More in particular, the present invention provides bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of pancreatitis-related pain, IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), dry eye disease and conjunctivitis sicca. These inhibitors were found to have a different inhibitory profile compared to diphenyl guanidinophenylethylphosphonates leading to a more pronounced effect on these conditions. |
| priorityDate |
2016-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |